- Home
- SST vs COEP Comparison
SST vs COEP Comparison
Compare SST & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | COEP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 300 | 7 |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 72.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | COEP |
|---|---|---|
| Price | $1.98 | $11.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 32.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $6.32 |
| 52 Week High | $11.30 | $21.41 |
Technical Indicators
Market Signals| Indicator | SST | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 19.29 | 45.69 |
| Support Level | $0.34 | $10.98 |
| Resistance Level | $4.61 | $13.23 |
| Average True Range (ATR) | 0.31 | 0.94 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 10.40 | 41.06 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.